Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448402) titled 'Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease' on Feb. 26.

Study Type: Observational [Patient Registry]

Primary Sponsor: Caja Costarricense de Seguro Social

Condition: Psoriasis Psoriasis Arthritis Psoriasis (PsO)

Intervention: Biological: Guselkumab (GUS)

Recruitment Status: Not recruiting

Date of First Enrollment: May 2026

Target Sample Size: 50

Countries of Recruitment: Costa Rica

To know more, visit https://clinicaltrials.gov/study/NCT07448402

Published by HT Digital Content Services with permission from Health Daily Digest....